< 生产厂家价格 >

5-氯-8-羟基-7-碘喹啉

5-氯-8-羟基-7-碘喹啉用途

Clioquinol(Iodochlorhydroxyquin)是一抗真菌化合物,近来被研究发现有抗AD和抗肿瘤活性。

点击显示

5-氯-8-羟基-7-碘喹啉名称

[ CAS 号 ]:
130-26-7

[ 中文名 ]:
氯碘羟喹

[ 英文名 ]:
Clioquinol

[中文别名 ]:

[英文别名 ]:

5-Chloro-8-hydroxy-7-iodoquinoline
Emaform
Bactol
5-21-03-00294 (Beilstein Handbook Reference)
5-chloro-7-iodo-8-hydroxy-quinoline
EINECS 204-984-4
Clioqinol
Vioform
cortin
T66 BNJ GG II JQ

5-氯-8-羟基-7-碘喹啉生物活性

[ 描述 ]:

Clioquinol(Iodochlorhydroxyquin)是一抗真菌化合物,近来被研究发现有抗AD和抗肿瘤活性。

[ 相关类别 ]:

信号通路 >> 自噬 >> 自噬

信号通路 >> 抗感染 >> 真菌

信号通路 >> 自噬 >> 自噬

研究领域 >> 感染

[参考文献]

[1]. Nguyen T, et al. Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model. Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11840-5.

[2]. Cao B, et al. Clioquinol induces pro-death autophagy in leukemia and myeloma cells by disrupting the mTOR signaling pathway. Sci Rep. 2014 Jul 18;4:5749.

[3]. Katsuyama M, et al. Clioquinol increases the expression of VGF, a neuropeptide precursor, through induction of c-Fos expression. J Pharmacol Sci. 2014;124(4):427-32.

[4]. Matlack KE, et al. Clioquinol promotes the degradation of metal-dependent amyloid-β (Aβ) oligomers to restore endocytosis and ameliorate Aβ toxicity. Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4013-8.

[相关活性小分子]

5-氯-8-羟基-7-碘喹啉物理化学性质

[ 密度 ]:
2.0±0.1 g/cm3

[ 沸点 ]:
350.4±37.0 °C at 760 mmHg

[ 熔点 ]:
175-183 °C

[ 分子式 ]:
C₉H₅ClINO

[ 分子量 ]:
305.500

[ 闪点 ]:
165.7±26.5 °C

[ 精确质量 ]:
304.910431

[ PSA ]:
33.12000

[ LogP ]:
3.86

[ 外观性状 ]:
奶油色的至褐色-黄色粉末几乎无气味的

[ 蒸汽压 ]:
0.0±0.8 mmHg at 25°C

[ 折射率 ]:
1.768

[ 储存条件 ]:
库房低温,通风,干燥,与食品原料分开存放

[ 水溶解性 ]:
<0.1 g/100 mL at 20 ºC

5-氯-8-羟基-7-碘喹啉MSDS

5-氯-8-羟基-7-碘喹啉毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: VC5075000

CHEMICAL NAME :: 8-Quinolinol, 5-chloro-7-iodo-

CAS REGISTRY NUMBER :: 130-26-7

BEILSTEIN REFERENCE NO. :: 0153637

LAST UPDATED :: 199710

DATA ITEMS CITED :: 29

MOLECULAR FORMULA :: C9-H5-Cl-I-N-O

MOLECULAR WEIGHT :: 305.50

WISWESSER LINE NOTATION :: T66 BNJ GG II JQ

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 11 gm/kg/36W

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - optic nerve neuropathy Sense Organs and Special Senses (Eye) - visual field changes

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human

DOSE/DURATION :: 1400 mg/kg/20D-I

TOXIC EFFECTS :: Brain and Coverings - recordings from specific areas of CNS

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >5 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 3400 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >5 gm/kg

TOXIC EFFECTS :: Nutritional and Gross Metabolic - weight loss or decreased weight gain

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 69 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 590 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 5 gm/kg

TOXIC EFFECTS :: Nutritional and Gross Metabolic - weight loss or decreased weight gain

TYPE OF TEST :: LD - Lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: >1 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - cat

DOSE/DURATION :: 400 mg/kg

TOXIC EFFECTS :: Liver - other changes

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: 250 mg/kg

TOXIC EFFECTS :: Liver - fatty liver degeneration Liver - other changes Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis)

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - guinea pig

DOSE/DURATION :: 175 mg/kg

TOXIC EFFECTS :: Liver - other changes

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - guinea pig

DOSE/DURATION :: 200 mg/kg

TOXIC EFFECTS :: Behavioral - ataxia

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Bird - chicken

DOSE/DURATION :: 5 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 15600 mg/kg/26W-I

TOXIC EFFECTS :: Kidney, Ureter, Bladder - changes in bladder weight Blood - pigmented or nucleated red blood cells Related to Chronic Data - death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 20 gm/kg/14W-I

TOXIC EFFECTS :: Spinal Cord - demyelination Spinal Cord - other degenerative changes

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 44 gm/kg/25W-I

TOXIC EFFECTS :: Liver - changes in liver weight Musculoskeletal - other changes

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 36600 mg/kg/17W-I

TOXIC EFFECTS :: Lungs, Thorax, or Respiration - acute pulmonary edema Lungs, Thorax, or Respiration - dyspnea Related to Chronic Data - death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 7 gm/kg/7D-I

TOXIC EFFECTS :: Lungs, Thorax, or Respiration - acute pulmonary edema Lungs, Thorax, or Respiration - dyspnea Related to Chronic Data - death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 9000 mg/kg

SEX/DURATION :: female 30 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Maternal Effects - ovaries, fallopian tubes Reproductive - Maternal Effects - uterus, cervix, vagina

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 1320 mg/kg

SEX/DURATION :: female 7-17 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4) Reproductive - Effects on Newborn - physical

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 528 mg/kg

SEX/DURATION :: female 7-17 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)

MUTATION DATA

TYPE OF TEST :: DNA inhibition

TEST SYSTEM :: Rodent - rat Cells - not otherwise specified

DOSE/DURATION :: 10 umol/L

REFERENCE :: JTSCDR Journal of Toxicological Sciences. (Japanese Soc. of Toxicological Sciences, 4th Floor, Gakkai Center Bldg., 4-16, Yayoi 2-chome, Bunkyo-ku, Tokyo 113, Japan) V.1- 1976- Volume(issue)/page/year: 12,97,1987 *** REVIEWS *** TOXICOLOGY REVIEW PRTODI "Progress in Toxicology," Zbinden, G., New York, Springer-Verlag, 1973 Volume(issue)/page/year: 1,68,1973 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X4788 No. of Facilities: 152 (estimated) No. of Industries: 2 No. of Occupations: 5 No. of Employees: 13895 (estimated) No. of Female Employees: 11269 (estimated)

点击显示

5-氯-8-羟基-7-碘喹啉安全信息

[ 符号 ]:

GHS06

[ 信号词 ]:
Danger

[ 危害声明 ]:
H301

[ 警示性声明 ]:
Missing Phrase - N15.00950417

[ 个人防护装备 ]:
Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges

[ 危害码 (欧洲) ]:
T:Toxic;

[ 风险声明 (欧洲) ]:
R25

[ 安全声明 (欧洲) ]:
S36/37/39-S45

[ 危险品运输编码 ]:
UN 2811 6.1/PG 3

[ WGK德国 ]:
3

[ RTECS号 ]:
VC5075000

[ 包装等级 ]:
III

[ 危险类别 ]:
6.1(b)

[ 海关编码 ]:
2933499090

5-氯-8-羟基-7-碘喹啉合成路线

5-氯-8-羟基-7-碘喹啉上下游产品

5-氯-8-羟基-7-碘喹啉上游产品

5-氯-8-羟基-7-碘喹啉下游产品

5-氯-8-羟基-7-碘喹啉海关

[ 海关编码 ]: 2933499090

[ 中文概述 ]:
2933499090. 其他含喹琳或异喹啉环系的化合物〔但未进一步稠合的〕. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%

[ 申报要素 ]: 品名, 成分含量, 用途, 乌洛托品请注明外观, 6－己内酰胺请注明外观, 签约日期

[ Summary ]:
2933499090. other compounds containing in the structure a quinoline or isoquinoline ring-system (whether or not hydrogenated), not further fused. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

5-氯-8-羟基-7-碘喹啉文献

A nuclear role for the respiratory enzyme CLK-1 in regulating mitochondrial stress responses and longevity.

Nat. Cell Biol. 17 , 782-92, (2015)

The coordinated regulation of mitochondrial and nuclear activities is essential for cellular respiration and its disruption leads to mitochondrial dysfunction, a hallmark of ageing. Mitochondria commu...

Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.

Chem. Res. Toxicol. 23 , 171-83, (2010)

Drug-induced liver injury is one of the main causes of drug attrition. The ability to predict the liver effects of drug candidates from their chemical structures is critical to help guide experimental...

A newly designed molecule J2326 for Alzheimer's disease disaggregates amyloid fibrils and induces neurite outgrowth.

Neuropharmacology 92 , 146-57, (2015)

Alzheimer's disease is a neurodegenerative disorder characterized by deposition of β-amyloid (Aβ) fibrils accompanied with progressive neurite loss. None of the clinically approved anti-Alzheimer's ag...

更多文献